Skip to main content

Recent News

Dr. John Cush
@RheumNow
Check the genetics in your patients with ILD A common misconception is that genetic variants don’t cause disease in adults, says Dr. Korf. According to Dr. Bogunovic, 1 in 4 adults will have a first manifestation of genetic error of immunity in adulthood. Genetics seems to be https://t.co/qRUV0oiu0a
Dr. John Cush
@RheumNow
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/PHm1fF3Tg4
Dr. John Cush
@RheumNow
Cardiovascular Risk in Axial Spondyloarthritis When a patient with axial spondyloarthritis patient sits in your clinic, their joint inflammation is only half the story. To truly achieve disease control, one should ask: “Am I consistently and aggressively screening them all for https://t.co/t0hLcKIowz
Dr. John Cush
@RheumNow
CAR T Gets the Spotlight. Are We Missing the B Cells That Matter? CAR T is having its moment in rheumatology. But William Robinson’s presentation at ACR Convergence 2026 raised a question I find even more compelling: are we failing to eliminate the right B cells with therapies https://t.co/uta77oaayo
Dr. John Cush
@RheumNow
Falls Hide in Plain Sight in Rheumatic Disease A patient with arthritis pitches forward onto her knees and wrists while bending to grab something. Another time she tries to get up and lands on the bed. Another time she uses a chair to lower herself to the floor. By the World https://t.co/kmmaRxhII0
Dr. John Cush
@RheumNow
Is It Still Inflammation? A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/fLGgnBCXS8
Dr. John Cush
@RheumNow
Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/tErmfDBy1r
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush
@RheumNow
Pre-RA: Antibodies Sort the Risk, Ultrasound Erosions Flag Severity Three ACR 2026 abstracts from the Leeds CCP cohort tested how to triage anti-CCP positive individuals with musculoskeletal symptoms. Serology and a few clinical items carried the prediction, while ultrasound https://t.co/91HG7xPS3o
Dr. John Cush
@RheumNow
Efgartigimod: A New Mechanism for Myositis? Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA https://t.co/cCgItPQSPS
Dr. John Cush
@RheumNow
“Age old” biomarkers in ILD and pulmonary fibrosis At #ACR26, there was a poster on senescence being increased in SARD-ILD (systemic autoimmune rheumatic disease – interstitial lung disease) including fibrotic (progressive pulmonary fibrosis), showing epithelial remodeling from https://t.co/cNxgqJIH8T
Dr. John Cush
@RheumNow
AI vs Rheumatologist? The Better Answer May Be Both Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo
Dr. John Cush
@RheumNow
Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ
Dr. John Cush
@RheumNow
Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt
Dr. John Cush
@RheumNow
Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw
×